Tango Therapeutics Soars on Erasca Partnership and Q4 Update
Tango Therapeutics shares jumped 36% following news of a strategic partnership with Erasca to develop vopimetostat for pancreatic and lung cancers, alongside its fourth-quarter financial update.
Earnings
